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Objectives. In this study we sought to investigate the prognostic
value of pharmacological stress echocardiography in women re-
ferred for chest pain, having unknown coronary artery disease.
Background. The noninvasive identification of a high-risk
subgroup among women with chest pain and unknown coronary
artery disease is an unresolved task to date.
Methods. A total of 456 women (mean [6SD] age 63 6 10
years) underwent pharmacological stress echocardiography with
either dipyridamole (n 5 305) or dobutamine (n 5 151) for
evaluation of chest pain and were followed-up for 32 6 19 months.
None of them had a previous diagnosis of coronary artery disease.
Results. No major complication occurred during stress testing.
Five tests (1.1%) were prematurely interrupted because of the
appearance of side effects. Echocardiographic positivity was iden-
tified in 51 patients. During the follow-up, 23 cardiac events
occurred: 3 deaths, 10 infarctions and 10 cases of unstable angina;
an additional 21 patients underwent coronary revascularization.
At Cox analysis, the echocardiographic evidence of ischemia was
found as the only independent predictor of hard cardiac events
(death, infarction) (odds ratio [OR] 5 27.5; 95% confidence
interval [CI] 5 (6.5 to 115.5; p 5 0.0000). When spontaneous
cardiac events (death, infarction and unstable angina) were
considered as endpoints, the positive echocardiographic result
(OR 5 23.9; 95% CI 5 8.6 to 66.8; p 5 0.0000) and family history
of coronary artery disease (OR 5 3.7; 95% CI 5 1.5 to 9.1; p 5
0.0037) were independently correlated with prognosis. By using an
interactive stepwise procedure, the prognostic value of stress
echocardiography was found to be incremental to that provided by
clinical variables, both considering hard and spontaneous cardiac
events as endpoints. The 3-year survival rate for the negative and
the positive population was respectively, 99.5% and 69.5% (p 5
0.0000) considering hard cardiac events, 99.2% and 50.6% (p 5
0.0000) considering spontaneous cardiac events.
Conclusions. Pharmacological stress echocardiography is safe,
highly feasible and effective in risk stratification of women with
chest pain and unknown coronary artery disease, also when hard
endpoints are considered. Its use can have relevant implications
in daily clinical practice for selection of patients needing further
investigations.
(J Am Coll Cardiol 1998;32:1975–81)
©1998 by the American College of Cardiology
The noninvasive identification of a high-risk subgroup among
women referred for chest pain having unknown coronary
artery disease (CAD) is a particularly difficult challenge in
daily clinical practice. In fact, although angina is about two
times more frequently the initial manifestation of CAD in
women than in men (65 vs. 35%) (1), in women it is associated
with high prevalence of normal epicardial coronary arteries
(2–5) and, therefore, with a generally benign prognosis (6–8).
Moreover, though exercise testing is the most widely used
method for the noninvasive prognostic assessment of CAD (9),
it is unreliable for evaluation of women since it carries a high
incidence of false positive responses (10–13), adversely affect-
ing the positive predictive value.
Echocardiography combined with physical or pharmacolog-
ical stress is an effective and not gender-related tool for
diagnostic purposes in women, having shown to provide signif-
icant higher diagnostic accuracy when compared with exercise
testing (14–17). Despite this, little is known (18) about the
value of stress echocardiography in risk stratification of women
with chest pain syndrome and unknown CAD. In particular,
the prognostic value of stress echocardiography in women has
been demonstrated for exercise (18), but not for pharmacolog-
ical stress echocardiography.
Based on these findings, we sought to determine the
prognostic value of pharmacological stress echocardiography
in a series of 456 women referred for chest pain, in the absence
of a previous diagnosis of CAD.
Methods
Patients. From November 1990 to October 1996, a total of
456 women (mean [6SD] age 63 6 10 years) underwent
pharmacological stress echocardiography with either dipyrida-
mole (n 5 305) or dobutamine (n 5 151) for evaluation of
chest pain, that was typical in 162 (36%) patients and atypical
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in the remaining 294 (64%), at two different Institutions. All
patients had interpretable echocardiographic images both in
resting condition and during stress testing. None of them had
known CAD, as defined by history of myocardial infarction,
unstable angina, coronary revascularization and/or angio-
graphically assessed stenosis (.50%) of any of the three
coronary arteries or their major branches (of the total cohort,
18 patients had previously [.6 months from stress testing]
undergone coronary angiography). Furthermore, no patient
had significant valvular disease, dilated or hypertrophic cardio-
myopathy.
In 445 (97.6%) patients, stress echocardiography was per-
formed after an adequate wash-out from antianginal drugs,
discontinuing beta-adrenergic blocking agents for at least 48 h
and long-acting nitrates and calcium channel blockers for at
least 24 h before the test. In the remaining 11 (2.4%) patients,
the test was performed under therapy with beta-blockers (n 5
6), calcium channel blockers (n 5 5) and/or nitrates (n 5 6).
All patients evaluated by dipyridamole were also not taking
phylline-containing drugs or beverages for at least 24 h.
In our echo laboratories, the choice of one test over the
other is governed by several possible factors such as clinical
issue, personal experience of individual echocardiographer and
known contraindications to the use of the available drug (such
as preexistence of complex ventricular arrhythmias in the case
of dobutamine or severe obstructive pulmonary disease in the
case of dipyridamole).
Stress protocol. Dipyridamole was given intravenously ac-
cording to the high dosage protocol (up to 0.84 mg/kg over 10
minutes) (19). Dobutamine was administered using an infusion
pump in steps of three minutes each with an initial dose of
5 mg/kg/min up to 40 mg/kg/min as a maximum (20). Starting in
April, 1993, the two protocols were modified with the coad-
ministration of atropine, if no signs of ischemia were detected
and the heart rate was inferior than 85% of the age- and
sex-predicted maximum at the end of the drug’s infusion
(21,22).
Two-dimensional echocardiogram and 12-lead electrocar-
diogram were continuously monitored during drug administra-
tion and until the heart rate has returned to baseline value
610% during the recovery phase. During the procedure, cuff
blood pressure and the electrocardiogram were recorded every
minute. Criteria for test interruption were: onset of obvious
new wall motion abnormalities, severe chest pain, horizontal or
downsloping ST-segment depression $2 mm, ST-segment el-
evation $1.5 mm, systolic blood pressure .220 mm Hg,
diastolic blood pressure .120 mm Hg, reduction in systolic
blood pressure $30 mm Hg, supraventricular or ventricular
tachyarrythmias, untolerable symptoms. Intravenous aminoph-
ylline (up to 240 mg) and metoprolol (up to 5 mg) were
promptly available to reverse the effects of dipyridamole and
dobutamine, respectively.
Echocardiographic analysis. Echocardiographic images
were obtained continuously from the standard apical and
parasternal views using commercially available instruments
(Sonos 2000, Hewlett Packard, Palo Alta, California; Sonotron
800 or System-Five, Vingmed, Santa Clara, California;
Ultramark-7, ATL; SSH 140, Toshiba, New York, New York).
From 1990 to 1995, images were continuously recorded using
S-VHS videotape recorders (Panasonic MD 830; Panasonic
7330; Panasonic 6200, Osaka, Japan) for off-line visual analy-
sis; starting in 1996, images were also recorded using a
quad-screen cine-loop system. Images were evaluated indepen-
dently by two expert observers. In case of disagreement, a third
observer, whose judgment was binding, evaluated the images.
Regional wall motion was semiquantitatively assessed using
a 16 segment model of the left ventricle according to the
recommendations of the American Society of Echocardiogra-
phy (23). A four point score was assigned to each segment as
follows: 1 5 normal; 2 5 hypokinesia; 3 5 akinesia; and 4 5
dyskinesia. A wall motion score index (WMSI) was obtained
dividing the sum of individual segment scores by the number of
considered segments. For each patient both the WMSI at
baseline and at the peak of drug infusion were obtained.
The result of a test was considered positive for ischemia
when any new or worsening of preexisting regional wall motion
abnormalities were detected. Moreover, electrocardiographic
(ECG) changes and chest pain were not considered per se as
markers of ischemia in absence of induced new wall motion
abnormalities.
Electrocardiographic analysis. Electrocardiographic
changes were considered significant for ischemia if a horizontal
or downsloping ST segment depression or elevation $0.1 mV
from baseline at 80 msec after the J point was assessed in at
least two contiguous leads. In the case of right bundle branch
block, the ST-segment shift was considered significant when it
also occurred in leads V5 and/or V6 (24).
Follow-up data. The mean length of the follow-up was
32 6 19 months. Follow-up data were obtained in 80% of cases
from telephone interviews with the patients and in the remain-
ing 20% of cases, from review of the patient’s hospital chart,
contact with the patient’s physician, or periodic visits to our
outpatient clinic.
The clinical events recorded during the follow-up were:
cardiac and noncardiac deaths, nonfatal myocardial infarction,
unstable angina and coronary revascularization procedures
(surgery or angioplasty).
The cause of death was elucidated from hospital or physi-
cian records; death was attributed to a cardiac origin in the
case of documentation of significant arrhythmias and/or car-
diac arrest, congestive heart failure or myocardial infarction.
Moreover, any death occurring suddenly out of the hospital
was ascribed to a cardiac cause. The diagnosis of acute
Abbreviations and Acronyms
CI 5 confidence interval
CAD 5 coronary artery disease
ECG 5 electrocardiographic
OR 5 odds ratio
WMSI 5 wall motion score index
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myocardial infarction was made on the basis of symptoms,
ECG changes and cardiac enzyme level increase. Unstable
angina was defined as angina at rest or change in pattern of
preexisting angina requiring hospitalization.
Statistical analysis. Values were expressed as 6 mean SD
for continuous variables and as frequency and percentage for
categorical variables. Continuous variables were compared
using the Student’s unpaired t test, while differences of cate-
gorical variables were assessed by the chi-square test. The
Kaplan–Meier method was used for estimation of infarction-
free survival and of spontaneously occurring event-free sur-
vival. For survival analysis, only one event was considered in
each patient. When patients underwent coronary revascular-
ization, they were censored at the time of the procedure.
Likewise, when patients died for noncardiac cause, they were
censored at the time of death. The differences in survival
curves were analyzed using the log-rank test. The capability of
certain variables to predict subsequent outcome was assessed
by the Cox proportional hazard model using univariate and
stepwise multivariate procedure (SPSS for windows, 1995,
Chicago, Illinois). Furthermore, in an attempt to investigate
the prognostic value of stress echocardiography incremental to
clinical data, an interactive stepwise procedure was performed,
where variables were included into the model in the same
order as in the clinical practice. Therefore, clinical data were
first analyzed and the global chi-square was calculated. Subse-
quently, a second step was created after addition of stress
echocardiography results to the independent predictors at first
step. The incremental prognostic value of the added variables
was assessed by comparison of the global chi-square at each
step. At each step, a p value #0.1 was taken as the required
level of significance for entering a variable into the model.
The differences in risk were expressed as odds ratio (OR)
with the corresponding 95% confidence interval (CI). The
variables included in the analysis were: age (, or $65 years),
typical chest pain, coronary risk factors (family history of CAD,
hypertension, hypercholesterolemia, cigarette smoking and
diabetes) and stress testing results (positive/negative echocar-
diographic result, WMSI at peak of drug infusion, ECG
changes during test and angina during test). A value of p ,
0.05 was considered statistically significant.
Results
Feasibility and side effects. No major complication oc-
curred. Of 456 tests, 5 were prematurely interrupted because
of the appearance of limiting side effects consisting in symp-
tomatic hypotension (n 5 2) and severe chest pain in the
absence of new wall motion abnormalities (n 5 1) during
dipyridamole, atrial fibrillation (n 5 1) and nonsustained
ventricular tachycardia (n 5 1) during dobutamine stress
testing. Therefore, the overall feasibility was 99% for dipyrid-
amole and 98.7% for dobutamine stress echocardiography. All
side effects reversed by antidote administration (aminophylline
for dipyridamole and metoprolol for dobutamine). Results for
these five patients, who underwent submaximal stress testing,
were included in the analysis as negative ones.
Stress echocardiography results. Echocardiographic evi-
dence of ischemia was identified in 51 (11%) patients. Of them,
34 had been investigated by dipyridamole and 17 by dobut-
amine stress echocardiography. In the positive population, the
WMSI increased from 1.03 6 0.12 in resting condition to
1.31 6 0.29 at peak of drug infusion.
Of the remaining 405 patients with negative echocardio-
graphic result, 68 (17%) developed an isolate ST-segment
depression during the test; of them, 31 (46%) had a history of
hypertension. Table 1 illustrates the clinical characteristics, as
well as the baseline and stress echocardiography findings, for
the positive and the negative population.
Follow-up data. Thirteen patients (2.8%) were lost to
follow-up; all of them had stress testing negativity. In the
remaining 443 patients, 23 cardiac events occurred: 3 cardiac
deaths, 10 myocardial infarctions, and 10 cases of unstable
angina. Moreover, five patients died of noncardiac causes:
three of cancer and two of stroke. They all had negative
echocardiographic result. Finally, 21 patients underwent coro-
nary revascularization with either surgery (n 5 10) or angio-
plasty (n 5 11), of whom 14 within three months (mean 1.2 6
0.7 months) and 7 after three months (mean 12.0 6 14.7
months) from stress testing. Table 2 illustrates the incidence of
cardiac events and revascularization procedures in the positive
and in the negative population. Of note was that no cardiac
death occurred among patients with negativity of test.
Considering the positive population, there were 10 events
(2 cardiac deaths, 4 infarctions, and 4 cases of unstable angina)
among 37 patients evaluated by dipyridamole, and 6 events (1
cardiac death, 3 infarctions, and 2 cases of unstable angina)
among 17 patients evaluated by dobutamine stress testing.
Finally, no cardiac event was experienced by 68 patients
who developed ECG but not echocardiographic positive re-
sponse during test.
Survival analysis. Seven variables were identified as uni-
variate predictors of hard cardiac events (death, myocardial
Table 1. Clinical, Baseline and Stress Testing Findings for the
Positive and the Negative Population
SE 1
(n 5 51)
SE 2
(n 5 405) p Value
Age (years) 65 6 8 62 6 10 , 0.05
Family history of CAD 24 (47%) 104 (26%) , 0.005
Hypercholesterolemia 24 (47%) 100 (25%) , 0.001
Hypertension 32 (63%) 159 (39%) , 0.005
Diabetes 4 (8%) 24 (6%) ns
Cigarette smoking 11 (21%) 50 (12%) ns
Typical chest pain 39 (76%) 123 (30%) , 0.0001
Resting WMSI 1.03 6 0.12 1.02 6 0.16 ns
Peak-stress WMSI 1.31 6 0.29 1.01 6 0.10 , 0.0001
ECG changes during test 30 (59%) 68 (17%) , 0.0001
Angina during test 28 (55%) 28 (7%) , 0.0001
Data presented are mean value 6 SD or number (%) of patients. SE 1/2 5
positive/negative echocardiographic result of stress testing; CAD 5 coronary
artery disease; WMSI 5 wall motion score index; ECG 5 electrocardiographic.
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infarction). In descending order they were: positive echocar-
diographic result (p 5 0.0000), peak-stress WMSI (p 5
0.0000), angina during test (p 5 0.0001), ECG changes during
test (p 5 0.0053), typical chest pain (p 5 0.0150), hypercho-
lesterolemia (p 5 0.0208) and family history of CAD (p 5
0.0251) (Table 3).
A nonsignificant higher positive predictive value was found
for dobutamine in comparison with dipyridamole stress echo-
cardiography (23.5% vs. 17.6%, p 5 0.62).
With a Cox analysis, the positive echocardiographic result
(OR 5 27.5; 95% CI 5 6.5 to 115.5; p 5 0.0000) was found as
the only independent predictor of hard cardiac events. The
infarction-free survival rate was 99.5% for patients with nega-
tive and 69.5% for patients with positive echocardiographic
result (p 5 0.0000) (Fig. 1).
Among clinical variables analyzed at first step of the
interactive stepwise procedure, typical chest pain (OR 5 3.6;
95% CI 5 1.1 to 12.1; p 5 0.0346) and hypercholesterolemia
(OR 5 3.1; 95% CI 5 1.0 to 9.5; p 5 0.0424) were independent
predictors of hard cardiac events; this model showed a global
chi-square of 15.8 (p 5 0.0012). In the second step, with the
addition of stress testing findings, the positive echocardio-
graphic result (OR 5 29.9; 95% CI 5 7.0 to 127.0; p 5 0.0000)
was the only prognostic predictor; the global chi-square of this
combined clinical and stress testing model was 81.0 (p 5
0.0000).
When spontaneous cardiac events (death, myocardial in-
farction and unstable angina) were considered as endpoints, six
variables showed univariate prognostic importance: positive
echocardiographic result (p 5 0.0000), angina during test (p 5
0.0000), peak-stress WMSI (p 5 0.0000), family history of
CAD (p 5 0.0002), ECG changes during test (p 5 0.0002) and
typical chest pain (p 5 0.0003) (Table 4).
No significant difference was evidenced for the positive
predictive value provided by dobutamine and dipyridamole
stress testing (35.3% vs. 29.4%, p 5 0.67).
At multivariate analysis, the positive echocardiographic
result (OR 5 23.9; 95% CI 5 8.6 to 66.8; p 5 0.0000) and
family history of CAD (OR 5 3.7; 95% CI 5 1.5 to 9.1; p 5
0.0037) were independently correlated with prognosis. The
event-free survival rate was 99.2% for patients with negative
and 50.6% for patients with positive echocardiographic result
(p 5 0.0000) (Fig. 2).
Of note, in the subset of patients with positive echocardio-
graphic result, the concomitant evidence of ischemia at ECG
was predictive of worse prognosis (p 5 0.06) (Fig. 3); on the
contrary, the presence or absence of ischemic ECG changes
did not portend different clinical outcome (p 5 0.24) among
patients having negative echocardiographic result of test. At
first model of the interactive stepwise procedure, including
clinical covariates only, typical chest pain (OR 5 4.4; 95%
CI 5 1.7 to 11.4; p 5 0.0022) and family history of CAD
(OR 5 3.4; 95% CI 5 1.5 to 8.2; p 5 0.0050) were predictors
of spontaneous cardiac events; the global chi-square was 30.4
(p 5 0.0000). After the addition of stress testing findings, the
positive echocardiographic result (OR 5 23.7; 95% CI 5 8.6 to
Figure 1. Cumulative survival rates free of hard cardiac events (car-
diac death and nonfatal myocardial infarction) in patients with nega-
tive (Neg) and positive (Pos) result of stress echocardiography.
Table 2. Cardiac Events According to the Result of Stress Echocardiography
Cardiac
death
Myocardial
infarction
Unstable
angina
CABG or
PTCA
Total
events
Total patients (n 5 443) 3 (0.7) 10 (2.3) 10 (2.3) 21 (4.7) 44 (9.9)
Echocardiographic result of test
positive (n 5 51) 3 (5.9)* 7 (13.7)* 6 (11.8)* 17 (33.3)* 33 (64.7)*
negative (n 5 392) 0 3 (0.8) 4 (1.0) 4 (1.0) 11 (2.8)
Data presented are number (%) of cardiac events. CABG 5 coronary artery bypass grafting; PTCA 5 percutaneous transluminal coronary angioplasty.
*Significantly different (p , 0.0001) from the result obtained in patients with negative result of test.
Table 3. Univariate Predictors of Hard Cardiac Events (Death,
Myocardial Infarction)
OR (95% CI) p Value
Positive echocardiographic result 36.9 (10.1–134.8) 0.0000
Peak-stress WMSI 15.3 (4.9–47.9) 0.0000
Angina during test 9.0 (3.0–26.7) 0.0001
ECG changes during test 4.7 (1.6–14.1) 0.0053
Typical chest pain 4.3 (1.3–14.0) 0.0150
Hypercholesterolemia 3.6 (1.2–10.8) 0.0208
Family history of CAD 3.5 (1.2–10.4) 0.0251
Age $ 65 years 1.8 (0.6–5.3) 0.2973
Cigarette smoking 0.6 (0.1–4.5) 0.6024
Diabetes 1.3 (0.2–9.9) 0.8070
Hypertension 0.9 (0.3–2.9) 0.9236
OR 5 odds ratio; CI 5 confidence interval; other abbreviations as in Table
1.
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64.9; p 5 0.0000) and family history of CAD (OR 5 3.7; 95%
CI 5 1.5 to 8.9; p 5 0.0034) had independent prognostic
importance; the global chi-square at this second step increased
to 146.7 (p 5 0.0000).
Discussion
This study shows that, in women referred for chest pain and
without prior diagnosis of CAD, the development of new wall
motion abnormalities during pharmacological stress has a
strong independent prognostic value, incremental to that pro-
vided by clinical data, when both hard and spontaneous cardiac
events are considered as endpoints. On the contrary, the
negative echocardiographic response to stress identifies a
low-risk population having cardiac event-rate of ,1% over 3
year follow-up. It is notable that patients developing ST-
segment depression in the absence of new wall motion abnor-
malities have an excellent prognosis (in our study none of them
experienced a cardiac event). Importantly, the low event rate
evidenced in our patients showing negative echocardiographic
result is comparable to that observed in patients with chest
pain and normal coronary angiography (25,26).
Comparison with previous studies. For a group of patients
having low prevalence of organic CAD and, therefore, a very
favorable prognosis, such as women complaining of chest pain,
it is difficult for any test to have capability to discriminate
among low-and high-risk subsets. Moreover, the results of one
test can be affected by the gender of the study population, such
as in the case of exercise electrocardiography, providing a high
incidence of false-positive responses in women (10–13) and,
consequently, the inability to accurately stratify patients’ risk.
The echocardiographic sign of ischemia during stress echocar-
diography is not gender-related and it is well-recognized that
this technique is accurate for the noninvasive diagnosis of
CAD in women (14–17). Despite this, little is known (18)
about the value of stress echocardiography in risk stratification
of women with chest pain syndrome. Heupler et al. (18) have
recently investigated the prognostic implications of exercise
echocardiography in a large series of women with chest pain,
having known (18%) or unknown (82%) CAD. When the
group of 416 patients without previous CAD was analyzed
using sequential Cox models, a positive echocardiographic test
result was the most powerful predictor of future cardiac events
(cardiac-related death, myocardial infarction and late revascu-
larization procedure), providing incremental prognostic value
to clinical and exercise data.
Our results, obtained using a pharmacological stress, ex-
pand data by Heupler et al., since they demonstrate an
independent and incremental prognostic power to clinical
variables by echocardiographic evidence of ischemia also when
hard cardiac events are considered as endpoints.
Stress test technique. Although dipyridamole and dobut-
amine act by different mechanisms, it is now clear that their
accuracy is virtually identical (27) as is their prognostic power
(28,29). In our opinion, the choice of one test over the other
can be made interchangeably according to the presence or
absence of specific contraindications of either drug. This is our
standard practice in daily routine, and we find it useful and
Figure 2. Cumulative survival rates free of spontaneous cardiac events
(cardiac death, nonfatal myocardial infarction and unstable angina) in
patients with negative (Neg) and positive (Pos) result of stress
echocardiography.
Figure 3. Cumulative survival rates free of spontaneous cardiac events
(cardiac death, nonfatal myocardial infarction and unstable angina)
according to the presence (1) or absence (2) of echocardiographic
(Echo) or electrocardiographic (ECG) signs of ischemia during phar-
macological stress testing.
Table 4. Univariate Predictors of Spontaneous Cardiac Events
(Death, Myocardial Infarction)
OR (95% CI) p Value
Positive echocardiographic result 31.3 (12.8–76.8) 0.0000
Angina during test 9.5 (4.2–21.7) 0.0000
Peak-stress WMSI 9.3 (3.6–24.0) 0.0000
Family history of CAD 5.0 (2.1–11.5) 0.0002
ECG changes during test 4.7 (2.1–10.6) 0.0002
Typical chest pain 5.7 (2.2–14.4) 0.0003
Hypercholesterolemia 2.0 (0.9–4.7) 0.0993
Age $ 65 years 1.8 (0.8–4.1) 0.1691
Hypertension 1.4 (0.6–3.2) 0.3915
Diabetes 1.5 (0.4–6.4) 0.5758
Cigarette smoking 1.0 (0.3–3.4) 0.9685
Abbreviations as in Tables 1 and 2.
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feasible. To use only one test, means for the cardiologist to
self-limit his diagnostic tools; to become familiar with both
means to get the most from this extremely flexible and versatile
technique (30).
Clinical implications. The results of this study have major
implications in clinical practice, since the use of pharmacolog-
ical stress echocardiography can be of help to discriminate
patients needing further invasive investigations from those
needing conservative treatment in the context of a low-risk
population, such as that represented by women with chest pain
and unknown CAD. However, stress echocardiography is not
to be considered an alternative, but rather a complementary
method to exercise testing, that remains the first choice of the
screening phase, being physiological, simpler, very low-cost
and providing a high negative predictive value, similar to that
shown by stress echocardiography (31). This last can be
recommended in selected conditions, such as in women with
equivocal or ischemic ECG response during exercise and in
women with the inability to exercise or whose electrocardio-
gram is uninterpretable.
Limitations of the study. Since it is an observational study,
the decision to perform coronary revascularization was taken
on the basis of the integration of stress testing results with the
individual clinical condition. As a consequence, revasculariza-
tion procedures were performed in 33% of patients with
positive and in only 1% of patients with negative echocardio-
graphic test results. It is presumable that this dropout process
can have lowered the positive predictive value of the test,
although the echocardiographic evidence of ischemia was
found as a very strong and independent predictor of outcome.
The stress protocol was not performed with coadministra-
tion of atropine in all patients since atropine was introduced in
the clinical practice (21,22) when the study was started. This
fact can have reduced the rate of positive echocardiographic
results, but its impact on prognosis seems not to have been
relevant, based on the excellent prognosis of patients with
echocardiographic negativity.
In the majority of the cases, the wall motion analysis was
performed from video tape and not in the cine-loop fashion.
Surely digital acquisition represents a more practical form of
stress testing storage, producing the on-line image evaluation
more easily and quickly. However, it has not been found to
afford significant diagnostic advantages when compared with
traditional video tape analysis (32).
Conclusions. Pharmacological stress echocardiography is
safe, highly feasible and effective in risk stratification of women
with chest pain syndrome and unknown CAD, also when hard
endpoints are considered. Its use can have relevant implica-
tions in daily clinical practice for selection of patients needing
further investigations.
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